1. Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies

   • Csaba Kerepesi
   • Tibor Bakacs
   • Colin C. Anderson

   Commentary Open access 09 March 2020 Pages: 683 - 687

   

2. Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density

   • Akinori Nukui
   • Takao Kamai
   • Ken-Ichiro Yoshida

   Original Article Open access 06 February 2020 Pages: 689 - 702

   

3. The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients

   • Pierre Rosenbaum
   • Cécile Artaud
   • Claude Leclerc

   Original Article 07 February 2020 Pages: 703 - 716

   

4. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients

   • Henna Kasanen
   • Micaela Hernberg
   • Anna Kreutzman

   Original Article Open access 08 February 2020 Pages: 717 - 730

   

5. Nonlinear response to cancer nanotherapy due to macrophage interactions revealed by mathematical modeling and evaluated in a murine model via CRISPR-modulated macrophage polarization

   • Fransisca Leonard
   • Louis T. Curtis
   • Hermann B. Frieboes

   Original Article 08 February 2020 Pages: 731 - 744

   

6. Activation of TLR4 signaling inhibits progression of osteosarcoma by stimulating CD8-positive cytotoxic lymphocytes

   • Kenichiro Yahiro
   • Yoshihiro Matsumoto
   • Yasuharu Nakashima

   Original Article 11 February 2020 Pages: 745 - 758

   

7. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients

   • Anne Fröhlich
   • Dennis Niebel
   • Jennifer Landsberg

   Original Article Open access 12 February 2020 Pages: 759 - 769

   

8. Tumor mutational load, CD8⁺ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients

   • Daan P. Hurkmans
   • Merian E. Kuipers
   • Sjoerd H. van der Burg

   Original Article Open access 12 February 2020 Pages: 771 - 777

   

9. Human inflammatory dendritic cells in malignant pleural effusions induce Th1 cell differentiation

   • Fei-fei Gu
   • Jing-jing Wu
   • Li Liu

   Original Article Open access 12 February 2020 Pages: 779 - 788

   

10. CD160 expression on CD8⁺ T cells is associated with active effector responses but limited activation potential in pancreatic cancer

    • Songyang Liu
    • Wei Zhang
    • Yingchao Wang

    Original Article 13 February 2020 Pages: 789 - 797

    

11. Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers

    • Julia Y. Tsang
    • Chun-Sing Ho
    • Gary M. Tse

    Original Article 13 February 2020 Pages: 799 - 811

    

12. Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia

    • Denise Risnik
    • Ana Colado
    • Mirta Giordano

    Original Article 13 February 2020 Pages: 813 - 824

    

13. CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma

    • Qiu-Zhong Pan
    • Qing Liu
    • Jian-Chuan Xia

    Original Article 14 February 2020 Pages: 825 - 834

    

14. LincRNA-p21 knockdown reversed tumor-associated macrophages function by promoting MDM2 to antagonize* p53 activation and alleviate breast cancer development

    • Lining Zhou
    • Yu Tian
    • Zhaoliang Su

    Original Article 15 February 2020 Pages: 835 - 846

    

15. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial

    • Masanori Noguchi
    • Gaku Arai
    • Kyogo Itoh

    Clinical Trial Report Open access 05 February 2020 Pages: 847 - 857

    

16. Long-term surviving cancer patients as a source of therapeutic TCR

    • Else Marit Inderberg
    • Sébastien Wälchli

    Focussed Research Review Open access 08 January 2020 Pages: 859 - 865

    

17. New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia

    • Stephanie Jordaens
    • Leah Cooksey
    • Barbara-ann Guinn

    Focussed Research Review Open access 22 January 2020 Pages: 867 - 877

    

18. Current progress in NK cell biology and NK cell-based cancer immunotherapy

    • Raquel Tarazona
    • Nelson Lopez-Sejas
    • Rafael Solana

    Focussed Research Review 04 March 2020 Pages: 879 - 899

    

19. “Tumor immunology meets oncology (TIMO) XV”, April 25th–27th 2019, Halle/Saale, Germany

    • André Steven
    • Chiara Massa
    • Barbara Seliger

    Meeting Report Open access 05 February 2020 Pages: 901 - 909